Bone Biologics Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corp. (BBLG) on May 18, 2023. The filing addresses a critical corporate event regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, or debt levels. The only financial metric referenced is the company's failure to meet the $1.00 minimum bid price requirement for 30 consecutive business days and the failure to meet the initial listing standard for stockholders' equity as of March 31, 2023.
Material Changes and Delisting Notice
- Nasdaq Non-Compliance: The company failed to regain compliance with Nasdaq Listing Rule 5450(a)(1) by the May 16, 2023 deadline.
- Delisting Notice: On May 18, 2023, Nasdaq notified the company that its common stock and warrants are subject to delisting due to continued non-compliance with the minimum bid price requirement.
- Equity Deficiency: The company was ineligible for a second 180-day grace period because it did not meet the stockholders' equity initial listing standard as of March 31, 2023.
Management Commentary and Outlook
- Appeal Process: Management plans to timely request a hearing before the Nasdaq Hearings Panel. This request will stay further delisting action pending the Panel's decision.
- Reverse Stock Split: On May 1, 2023, shareholders approved a reverse stock split with a ratio between 1-for-20 and 1-for-50. The Board of Directors will determine the exact ratio to increase the bid price and regain compliance.
- Contingency Plan: If delisted from Nasdaq, the company expects its securities to trade on the OTC Markets platform.
Investor Verification Checklist
- Verify the exact reverse stock split ratio selected by the Board of Directors.
- Monitor the status of the appeal hearing before the Nasdaq Hearings Panel.
- Confirm the company's stockholders' equity position to ensure it meets continuing listing requirements once the bid price is restored.
- Check for potential trading suspension or transfer to OTC Markets if the appeal is unsuccessful.